Goldman Sachs Group Inc Silence Therapeutics PLC Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Goldman Sachs Group Inc holds 36,885 shares of SLN stock, worth $176,679. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,885
Previous 30,632
20.41%
Holding current value
$176,679
Previous $557,000
54.58%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding SLN
# of Institutions
66Shares Held
24.6MCall Options Held
500Put Options Held
5K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$14.5 Million3.41% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$13.6 Million0.86% of portfolio
-
Redmile Group, LLC San Francisco, CA2.4MShares$11.5 Million1.29% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.86MShares$8.89 Million1.01% of portfolio
-
Morgan Stanley New York, NY1.66MShares$7.97 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $172M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...